Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neurocrine Biosciences (NBIX) Invested Capital (2016 - 2025)

Neurocrine Biosciences (NBIX) has disclosed Invested Capital for 15 consecutive years, with $3.3 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Invested Capital rose 25.62% year-over-year to $3.3 billion, compared with a TTM value of $3.3 billion through Dec 2025, up 25.62%, and an annual FY2025 reading of $3.3 billion, up 25.62% over the prior year.
  • Invested Capital was $3.3 billion for Q4 2025 at Neurocrine Biosciences, up from $3.0 billion in the prior quarter.
  • Across five years, Invested Capital topped out at $3.3 billion in Q4 2025 and bottomed at $1.2 billion in Q1 2021.
  • Average Invested Capital over 4 years is $2.3 billion, with a median of $2.5 billion recorded in 2024.
  • The sharpest move saw Invested Capital dropped 1.0% in 2021, then surged 48.94% in 2024.
  • Year by year, Invested Capital stood at $1.3 billion in 2021, then surged by 78.46% to $2.4 billion in 2023, then rose by 7.81% to $2.6 billion in 2024, then rose by 25.62% to $3.3 billion in 2025.
  • Business Quant data shows Invested Capital for NBIX at $3.3 billion in Q4 2025, $3.0 billion in Q3 2025, and $2.7 billion in Q2 2025.